& O'Byrne, P
Retatrutide for type 2 diabetes: Phase 2 trial results (36-week study, HbA1c reductions, weight loss) New England Journal of Medicine (2023) Jastreboff AM, et al
For the difference from steroids see are peptides steroids
Who can apply Applications are open to universities and research institutes, hospitals and clinical centres, non-profit research organisations and foundations, patient advocacy organisations (PAOs), and SMEs, the latter subject to specific funding provisions
RNA sequencing and pathway enrichment analysis show FOXO4-DRI significantly downregulates extracellular matrix-receptor interaction pathways, including fibronectin (Fn1), tenascin C (Tnc), and thrombospondin 2 (Thbs2), all critical components of fibrotic tissue architecture